Hospital Bed. Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Ramsay Health Care (ASX: RHC) has delivered a sharp improvement in FY26 earnings, with stronger hospital activity, improved operating performance and tighter cost management helping the healthcare group lift both underlying and statutory profit.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

The hospital operator reported net profit after tax of $329.2 million for the year ended June 30, compared with $24 million a year earlier. The result was ahead of the $311.4 million Visible Alpha consensus.

Revenue increased to $18.7 billion, from $17.84 billion in FY25, while underlying NPAT rose 22.9% to $364.1 million. Underlying EBIT also increased 11.8% to $1.162 billion, with underlying earnings per share rising 27% to 151.0 cents.

Ramsay said its Australian hospital operations continued to build momentum, with higher patient activity, an increase in more complex cases, better utilisation of operating theatres and improved cost control supporting the result.

The group also recorded positive net cash flow across its Australian and UK businesses. Group EBIT margin improved by 30 basis points to 6.2%, while returns on invested capital also strengthened.

The improved earnings performance has flowed through to shareholders, with Ramsay declaring a fully franked final dividend of 48.5 cents per share, taking the full year payout to 91 cents per share.

Chief executive Natalie Davis pointed to stronger transformation across the Australian business, alongside continued clinical performance and improvements in capital returns.

Looking ahead, Ramsay expects further EBIT growth and margin improvement in FY27 as it continues to focus on hospital activity, cost management and capital discipline.

Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

rhc by the numbers
More From The Market Online

Pro Medicus signs $25M contract with US-based Valley Health

Pro Medicus' US subsidiary Visage Imaging has signed a seven-year, $25 million contract with Valley Health…

Pro Medicus posts 130% profit surge as forward contract book hits $1.34b

Pro Medicus posts a 130.3% rise in FY26 NPAT to $265.3m as revenue reaches $261.7m and…
Mesoblast research conept

Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches

Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low…

AVITA Medical raises 2026 outlook after record second quarter

AVITA Medical has raised its 2026 revenue guidance after delivering record quarterly revenue, while forecasting cash…